Lilly to acquire US radiopharmaceutical company POINT for $1.4bn
POINT has two potential candidates in late-phase development, with several others in earlier stages of development, operates a 180,000ft2 manufacturing facility in Indianapolis, US, and a research and development centre in Toronto, Canada